Skip to content
1690-Myeloid Reprogramming to Enhance Radiotherapy episode artwork

Oct 19, 2026 26 min

1690-Myeloid Reprogramming to Enhance Radiotherapy

from Paper Talk

Research demonstrates that radiotherapy frequently induces immunosuppressive myeloid cells, which drive therapeutic resistance and tumor progression. When radiation is administered, it triggers a p53-TET2 axis that oxidizes methylcytosine marks on chromatin-associated RNAs, leading to chromatin compaction and the suppression of crucial interferon pathways. Conversely, the genetic deletion or pharmacological inhibition of TET2 prevents this suppressive cascade, preserving chromatin accessibility and shifting monocyte differentiation toward immunostimulatory myeloid-derived activating cells. These activating cells successfully restore cytotoxic CD8+ T cell immunity and significantly enhance the efficacy of combined radiotherapy and immunotherapy. Ultimately, targeting this epigenetic pathway offers a promising therapeutic strategy to overcome treatment resistance and suppress metastatic spread. References: Ji F, Zheng L, Chen D, et al. Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis[J]. Cancer Cell, 2026. 前往小宇宙评论区与主播互动

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

1690-Myeloid Reprogramming to Enhance Radiotherapy

0:00 26:10

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Paper Talk?

This episode is 26 minutes long.

When was this Paper Talk episode published?

This episode was published on October 19, 2026.

Can I download this Paper Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.